Table 1 Correlations between ARHGAP9 expression and clinicopathological feathers in AML from TCGA cohort
From: The role of ARHGAP9: clinical implication and potential function in acute myeloid leukemia
Patient characteristics | ARHGAP9 expression | ||
|---|---|---|---|
Low (n = 76) | High (n = 75) | p | |
Sex, male/female | 38/38 | 45/30 | 0.217 |
Median age, years (range) | 53.5 (21–77) | 60 (21–88) | 0.091 |
Median BM blasts, % (range) | 75 (30–100) | 69 (30–99) | 0.071 |
Median WBC, × 109/L (range) | 13.35 (0.4–137.2) | 27.6 (0.6–223.8) | 0.194 |
Median PB blasts, % (range) | 40 (0–97) | 39 (0–96) | 0.322 |
FAB classifications | |||
 M0 | 6 | 9 | 0.399 |
 M1 | 12 | 24 | 0.019 |
 M2 | 14 | 23 | 0.067 |
 M3 | 14 | 0 | 0 |
 M4 | 16 | 5 | 0.011 |
 M5 | 10 | 1 | 0.005 |
 M6 | 1 | 0 | 1 |
 M7 | 1 | 0 | 1 |
 NA | 1 | 0 | 1 |
Cytogenetics | |||
 Normal | 24 | 37 | 0.026 |
 t(8;21) | 3 | 4 | 0.719 |
 t(15;17) | 14 | 0 |  < 0.001 |
 inv.(16) | 7 | 3 | 0.327 |
 + 8 | 5 | 3 | 1 |
 11q23 | 7 | 1 | 0.063 |
 -7/del(7) | 2 | 4 | 0.442 |
 Complex | 5 | 13 | 0.041 |
 Others | 8 | 8 | 0.978 |
 No data | 1 | 2 | 1 |
Risk level | |||
 Good | 24 | 7 | 0.001 |
 Intermediate | 34 | 45 | 0.060 |
 Poor | 17 | 21 | 0.453 |
 NA | 1 | 2 | 1 |